Pfizer COVID-19 vaccine EUA submission – Timeline to doses

Pfizer’s COVID-19 vaccine has been submitted to the US FDA for emergency use authorization, paving the way for use of the drug potentially as soon as mid-December 2020. The vaccine candidate, co-developed with German firm BioNTech, has indicated a 95-percent success rate in Phase 3 trials, with no signs of serious safety concerns or side-effects. Indeed, as the trial concluded, … Continue reading